INTRODUCTION {#sec1-1}
============

Ginseng is Chinese traditional herbal medicine; ginsenosides are the main bioactive ingredients. At present, there are many monomer components had been separated.\[[@ref1]\] The ginsenoside Rg~3~ is the saponin from Ginseng, its structure belongs to protopanaxadiol type saponin in monomer, the molecular formula is C~42~H~72~O~13~, and its relative molecular mass is 784.\[[@ref2]\] In various isolated saponins, the anti-tumor effect of Rg~3~ was the most significant and had been widely used in clinical treatment.\[[@ref3][@ref4]\] The ginsenoside Rg~3~ is the main active ingredient in Shenyi capsule, the first anti-tumor Chinese medicine, in China. Up to now, there have been many reports about ginsenoside Rg~3~ *in vitro* and *in vivo* pharmacokinetic (PK) studies.\[[@ref5][@ref6][@ref7]\] It was reported that ginsenoside Rg~3~ may be prodrug,\[[@ref8][@ref9][@ref10]\] and it can be hydrolysated ginsenoside Rh~2~ and ginsenoside Rh~2~ played an important role in anti-cancer action.\[[@ref11][@ref12][@ref13]\] However, there is no page about detecting ginsenoside Rh~2~ *in vivo* after oral ginsenosides Rg~3~, and also no study on PKs of ginsenoside Rg~3~ in tumor-bearing plasma. Therefore, the purpose of this study was to develop a sensitive, simple, and accurate high-performance liquid chromatography (HPLC) method to simultaneously determine the concentration of ginsenoside Rg~3~ and ginsenoside Rh~2~ in normal and tumor-bearing rat plasma and to investigate, and compare the PK parameters of ginsenoside Rg~3~ and ginsenoside Rh~2~ after oral administration of ginsenoside Rg~3~.

MATERIALS AND METHODS {#sec1-2}
=====================

Materials and chemicals {#sec2-1}
-----------------------

Pure ginsenoside Rg~3~ was obtained from Prof. Fu Li (Dalian Fusheng Natural Drug Development Co., Ltd). The purities of ginsenoside Rg~3~ was determined to be up to 98% by HPLC. Ginsenoside Rh~2~ (\>98%) and the internal standard (IS) ginsenoside Rb~1~ (\>98%) were purchased from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). The solvents (HPLC grade) used for chromatographic analysis were purchased from Fisher Company Inc., USA. Deionized water was prepared in a Mill-Q academic water purification system (Millipore, Bedford, MA, USA). All the other reagents were of analytical grade and provided by Kermel Chemical Co., (Tianjin, China).

Apparatus and chromatographic conditions {#sec2-2}
----------------------------------------

The concentrations of two ginsenosides in plasma were assayed using reverse-phase HPLC (Agilent 1200 series) equipped with a variable wavelength ultraviolet (UV) detector and pump (Agilent model G1314A VWD). The separation was accomplished on a Welch Ultimate AQ-C~18~ column (150 mm × 4.6 mm, 5 μm particle size). The mobile phase was composed of acetonitrile (A): Water (B) (0 → 5 min, 35:65; 5 → 10 min, 60:40; 10 → 20 min, 60:40; v/v) at a flow rate of 1.0 mL/min with gradient elution. The column temperature was 30°C. The detector was set at 203 nm. The injection volume was 20 μL. The chromatographic run time for each analysis was 35.0 min.

Animals {#sec2-3}
-------

Male Wistar rats, weighing 200--250 g, were obtained from Liao Ning Chang Sheng Biotechnology Co., Ltd., (Benxi, China). Animal welfare and experimental procedures were strictly in accordance with the Guide for the Care and Use of Laboratory Animals (US National Research Council, 1996) and the related ethics regulations of Liaoning University of Traditional Chinese Medicine. Rats were housed in an air-conditioned animal quarter at a temperature of 22°C ± 2°C and a relative humidity of 50% ± 2%. All animals received food and water *ad libitum*. The animals were acclimatized to the facilities for 5 days and then fasted with free access to water for 24 h prior to each experiment.

Animal model {#sec2-4}
------------

Walker 256 carcinosarcoma cells were purchased from Beijing AnBona Science and Technology Co., Ltd., (Beijing, China). Tumor cells for the establishment of the experimental animal model were obtained from ascitic fluid in Wistar rats, after two cycles of 7 days cell passage by intraperitoneal injection of 10^7^ Walker 256 carcinoma cells. When cell harvesting dilute the tumor cells suspension to 10^7^ cells/mL with sterile saline.

After 3 days of acclimatization in metabolic cages, rats were randomly divided into two groups: Model group (*n* = 6, labeled M01−M06) and control group (*n* = 6, labeled C01−C06). The rats in model group were established by subcutaneous injection of a 200 μL suspension of Walker 256 carcinosarcoma cells (1 × 10^7^ cells/mL) into the right armpit while the control group was injected with an equal volume of sterile saline.

Preparation of stocks, calibration samples, and quality control samples {#sec2-5}
-----------------------------------------------------------------------

The stock solutions were prepared by dissolving 2.73 mg of ginsenoside Rg~3~, 5.52 mg of ginsenoside Rh~2~, and 5.27 mg IS in 10 mL methanol, respectively. A series of mixture standard working solutions with concentrations of 5.46, 6.83, 13.7, 27.3, 54.6, 81.9, 109 μg/mL for ginsenoside Rg~3~ and 0.552, 1.10, 2.21, 4.17, 5.70, 8.28, 11.4 μg/mL for ginsenoside Rh~2~, were obtained by diluting the mixture of the stock standard solutions with methanol. The IS working solution was prepared by diluting the IS stock solution with methanol. All solutions were stored at 4°C.

Sample preparation {#sec2-6}
------------------

Plasma samples (200 μL) were spiked with 50 μL IS, and the mixtures were extracted with 1000 μL acetonitrile by vortex mixing for 3 min. After centrifugation at 4000 *× g* for 5 min, the solution was transferred to a polypropylene tube and dried under nitrogen gas at room temperature. The plasma residue was reconstituted in 50 μL of methanol, respectively. The injection volume was 20 μL for analysis.

Method validation {#sec2-7}
-----------------

The validation has been performed according to the Food and Drug Administration guidelines.

### Linearity and quantification {#sec3-1}

The method was fully validated for its specificity, linearity, lower limits of detection (LLOD), lower limits of quantification (LLOQ), accuracy, and precision. The LLOD was determined during the evaluation of linear range of the calibration curve and is defined as the lowest concentration level resulting in a signal-to-noise ratio of 3:1. The LLOQ was determined as the lowest concentration of the analyte in rat plasma and tissue that could be quantified with an inter-assay relative standard deviation (%RSD) lower than 20% and with accuracy rates between 80% and 120%.

### Accuracy and precision {#sec3-2}

The precision and accuracy of the method was evaluated by analyzing quality control (QC) samples with different concentrations. The intra-day variability was determined by assaying five replicates on the same day, and the inter-day variability was determined by assaying five replicates on three consecutive days. Precision was defined as the coefficient of variation expressed as a percentage. The accuracy of these samples was determined by comparing the calculated concentration obtained from the calibration curve with the known concentration.

### Extraction recovery {#sec3-3}

Extraction recoveries from rat plasma were determined at three concentrations by comparing the peak areas extracted from rat plasma with those of the same quantities added to methanol.

### Stability {#sec3-4}

Stability of ginsenoside Rg~3~ and ginsenoside Rh~2~ in rat plasma was assessed with QC samples (*n* = 3) stored at −20°C for 30 days. Freeze-thaw stability of ginsenoside Rg~3~ and ginsenoside Rh~2~ in rat plasma was investigated with QC samples (*n* = 3) subjected to three freeze/thaw cycles.

Pharmacokinetic study {#sec2-8}
---------------------

The normal Wistar rats (*n* = 6) and Walker 256 tumor-bearing rats (*n* = 6) were assigned to receive a ginsenoside Rg~3~ solution by oral administration at the dose of 50 mg/kg of ginsenoside Rg~3~, respectively. Serial blood samples (0.4 mL) were obtained *via* the rats' orbital vein at 1, 1.5, 2, 3, 4, 6, 8, and 12 h after administration and were collected into heparinized centrifuge tubes. The blood samples were immediately centrifuged at 667 *× g* for 10 min at room temperature. The plasma samples were analyzed by the previously described methods.

Statistical analysis {#sec2-9}
--------------------

The content of ginsenoside Rg~3~ and ginsenoside Rh~2~ in plasma at different times were evaluated by means of linear regression analysis. All data were calculated using Microsoft Excel 2003 (Microsoft). The relevant PK parameters were calculated using the computer program DAS 2.0 (Chinese Society of Mathematical Pharmacology, Beijing, China) from the Chinese Pharmaceutical Association.

RESULTS AND DISCUSSION {#sec1-3}
======================

High-performance liquid chromatography assay {#sec2-10}
--------------------------------------------

The selectivity of the method was evaluated by analyzing blank plasma samples prior to administration. The chromatograms of the plasma and organs are shown in [Figure 1](#F2){ref-type="fig"}. Ginsenoside Rb~1~ (IS), ginsenoside Rg~3~, and ginsenoside Rh~2~ were well separated at 7.064, 13.250, and 18.822 min, respectively with no endogenous interference.

![Chromatograms of rat plasma samples: (a) Blank plasma; (b) blank plasma spiked with internal standard, ginsenoside Rg~3~ and ginsenoside Rh~2~; (c) plasma sample obtained 2 h after oral administration of ginsenoside Rg~3~ at a dose of 50 mg/kg to rat; (internal standard, *t*~R~ = 7.064 min; ginsenoside Rg~3~, *t*~R~ = 13.250 min;;ginsenoside Rh~2~, *t*~R~ = 18.822 min)](PM-12-21-g002){#F2}

The linear calibration curves were obtained in the given concentration range of ginsenoside Rg~3~ or ginsenoside Rh~2~ in plasma samples, respectively. The standard curves were fitted to a first-degree polynomial, *Y* = aX + b, where *Y* was the peak area of ginsenoside Rg~3~/IS or ginsenoside Rh~2~/IS, *a* and *b* were constants, and *X* was the concentration (μg/mL) of ginsenoside Rg~3~ or ginsenoside Rh~2~. Calibration curves were found to be linear over the calibration range of 5.46--109 μg/mL for ginsenoside Rg~3~ and 0.552--11.4 μg/mL for ginsenoside Rh~2~ in rat plasma. All curves have correlation coefficients of \>0.99. The LLOQ of ginsenoside Rg~3~ and ginsenoside Rh~2~ were 5.46 and 0.552 μg/mL for plasma with the RSD \<20%.

The RSD for the intra-day (repeatability) and inter-day precision ranged from 1.13% to 10.7%, for QC standards. The percentage of extraction recoveries of ginsenoside Rg~3~ and ginsenoside Rh~2~ for plasma were between 75.6% and 91.1%, respectively. These data indicated that the sample preparation method were satisfied and resulted in no appreciable matrix effect for ginsenoside Rg~3,~ ginsenoside Rh~2~ and IS.

The stability tests were designed by taking into account the anticipated conditions that real samples may experience. The RSD of the stability studies were 5.75--12.8%, respectively.

Pharmacokinetics of ginsenoside Rg~3~ and ginsenoside Rh~2~ after oral administration of ginsenoside Rg~3~ to rats {#sec2-11}
------------------------------------------------------------------------------------------------------------------

The method presented here was successfully used to quantify the ginsenoside Rg~3~ and ginsenoside Rh~2~ in rat plasma after oral administration of ginsenoside Rg~3~. The concentration-time profiles of the ginsenoside Rg~3~ and ginsenoside Rh~2~ are shown in [Figure 2](#F3){ref-type="fig"}. According to the *F*-test and the Akaike\'s information criterion, a two-compartment PK model fitted best the plasma data of the ginsenoside Rg~3~ and ginsenoside Rh~2~. The calculated PK parameters are listed in [Table 1](#T1){ref-type="table"}.

![The mean plasma concentration-time curves of ginsenoside Rg~3~ and ginsenoside Rh~2~ after oral administration of ginsenoside Rg~3~ to normal rat and tumor-bearing at different doses. (a) ginsenoside Rg~3~ and (b) ginsenoside Rh~2~](PM-12-21-g003){#F3}

###### 

Pharmacokinetic parameters for ginsenoside Rg~3~ and gingsenoside Rh~2~ in normal rats and tumor-bearing rats (mean±SD, *n*=6) after a single oral administration of ginsenoside Rg~3~

![](PM-12-21-g004)

The noncompartmental model was applied to the PK evaluation of ginsenoside Rh~2~ against the original compound ginsenoside Rg~3~. Ginsenoside Rg~3~ exhibited a rapid and poor absorption phase followed by a sharp but lasting disappearance of ginsenoside Rh~2~. The concentration peak values of ginsenoside Rg~3~ were much higher than ginsenoside Rh~2~ indicating that ginsenoside Rg~3~ should also be a major compound *in vivo*. The data suggested that ginsenoside Rg~3~ were a major compound for pharmacological effects because there were significant differences in the area under the plasma level/time curve (AUC~\[0-t\]~) between ginsenoside Rg~3~ and ginsenoside Rh~2~.

After oral administration of Rg~3~, the AUC values, terminal half-life, and concentration maximum of ginsenosides Rg~3~ and ginsenoside Rh~2~ in normal rats were higher than those in the tumor-bearing rats. The result showed that the absorption of Rg~3~ in tumor-bearing was lower than in normal rats, but the clearance is higher than normal mice. It may be that the tumor changes rats' body environment, which affect the absorption and metabolism of drug. Therefore, the dosage needs to be adjusted appropriately, according to the practical applications and achieve the desired therapeutic effect.

CONCLUSION {#sec1-4}
==========

Our study is the first evaluation of the plasma PKs of ginsenoside Rg~3~, as well as its metabolite, ginsenoside Rh~2~. The ginsenoside Rg~3~ and ginsenoside Rh~2~ have been quantified by HPLC-UV. The validated method was simple, fast, reproducible, and suitable for the research of ginsenoside Rg~3~ and ginsenoside Rh~2~ in rat plasma with ginsenoside Rb~1~ as the IS. The assay utilized an acetonitrile extraction method and a reversed-phase separation with sufficient selectivity and sensitivity. The evaluation of the PKs of ginsenoside Rg~3~ and ginsenoside Rh~2~ will help further the understanding of their pharmacological activity and clinical use. We need to take caution when extrapolating PK and exposure data from healthy animals to diseased animals in designing pharmacological studies.
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